Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boston Scientific has reported net sales of $1.96bn for the first quarter ended March 31, 2010, compared to $2bn for the comparable period in 2009.
Subscribe to our email newsletter
Boston Scientific has posted a net loss of $1.58bn for the first quarter 2010, or $1.05 per diluted share, compared to $13m, or $0.01 per diluted share, for the prior year period. Operating loss was $1.48bn, compared to an operating income of $11m for the year ago period.
Boston Scientific estimates net sales for the second quarter of 2010 of between $1.825bn and $1.925bn. Adjusted earnings, excluding restructuring and restructuring-related costs and amortization expense, are estimated to range between $0.06 and $0.10 per share. Boston Scientific estimates results on a GAAP basis of between a loss of $0.03 and income of $0.02 per share.
Ray Elliott, president and CEO of Boston Scientific, said: “It was a challenging quarter including a settlement to resolve long-standing litigation, and the CRM ship hold and product removal actions. However, the return of Cognis and Teligen to the US market – coupled with exceptional cash flow and a strong cadence from our new product pipeline – were positive factors.”